Zenrelia: A new treatment to elevate care in canine allergic and atopic dermatitis (LVS25)

Presented at London Vet Show 2025.

20 Nov 2025 11:30 - 12:30 Gallery Suite 22

This session will focus on your treatment targets when treating atopic patients, data from the Zenrelia clinical trials and real-world experience with Zenrelia from some of the UK’s leading dermatologists.

Learn about Zenrelia (ilunocitinib), Elanco’s new once-daily JAK inhibitor for the treatment of canine allergic and atopic dermatitis which brings 45% more itchy dogs back to normal compared with Apoquel* [1]. Launched in the UK this Summer, Zenrelia has already been used to treat over 800,000 dogs in Brazil, the USA, Japan and Canada since its first launch last year [2].

*77% of dogs treated with Zenrelia achieved PVAS <2 by Day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2).[1] 1. Forster S et al. Vet Dermatol. 2025 Apr;36(2):165–76. 2. Elanco Animal Health. Elanco Global Sales Data. Sept 2025.

• Learn about what to aim for when treating atopic dermatitis
• Learn about how Zenrelia brings more itchy dogs back to normal
• Learn about how best to use Zenrelia in your every day practice to achieve better outcomes for your patients

Speakers
Victoria Robinson, BVM&S BSc CertAVP (VD) DipECVD MRCVS, RCVS and European Specialist in Veterinary Dermatology
Timothy Jones, MA VetMB MRCVS, Veterinary Technical Consultant - Elanco Animal Health UK
Natalie Barnard, BVetMed CertVD DipECVD MRCVS, RCVS and European Specialist in Veterinary Dermatology - Bristol Vet Specialists

Delivered by: